Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 68071-3568

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 68071-3568). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pdp (68071 3568 8)

Pdp (68071 3568 8)
Label for Rizatriptan Benzoate ODT 10 mg orally disintegrating tablets by NuCare Pharmaceuticals, Inc. The label indicates a quantity of 18 tablets and includes NDC 68071-3568-8. It states each tablet contains 14.53 mg Rizatriptan Benzoate equivalent to 10 mg Rizatriptan. Storage instructions specify controlled temperature 68-77°F. The label includes lot, expiration, and serial number placeholders along with warning to keep out of reach of children.*
FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
A Kaplan-Meier plot titled "Estimated Probability of Achieving an Initial Headache Response by 2 Hours in Pooled Studies 1, 2, 3, and 4" showing estimated probability of headache response over 2 hours post-dose. It compares placebo, Rizatriptan Benzoate Tablets 5 mg, and Rizatriptan Benzoate Tablets 10 mg in outpatient trials.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In P (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In P (Rizatriptan Fig2)
A Kaplan-Meier plot showing the estimated probability of patients taking a second dose of Rizatriptan Benzoate tablets or other medication for migraines over 24 hours after the initial dose. The graph compares placebo, Rizatriptan Benzoate 5 mg tablets, and 10 mg tablets with probability of medication use on the vertical axis and hours post-dose on the horizontal axis, based on pooled data from four clinical trials.*
FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)
Kaplan-Meier plot depicting the estimated probability of achieving an initial headache response over 2 hours after dosing with Rizatriptan Benzoate orally disintegrating tablets at 5 mg and 10 mg doses versus placebo. The graph shows time post-dose on the x-axis and probability of response on the y-axis, with distinct curves for placebo, 5 mg, and 10 mg tablets based on pooled clinical study data.*
FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose O (Rizatriptan Fig4)

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose O (Rizatriptan Fig4)
A Kaplan-Meier plot showing the estimated probability over 24 hours that patients take a second dose of Rizatriptan Benzoate orally disintegrating tablets (5 mg and 10 mg) or placebo for migraine treatment. The X-axis represents hours post-dose, and the Y-axis shows the estimated probability of taking remedication or rescue treatment. The plot compares three curves: placebo, 5 mg, and 10 mg Rizatriptan Benzoate tablets.*
FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)
A line chart depicting the observed percentage of patients reporting no headache pain up to 2 hours post-dose in Study 7, comparing Rizatriptan Benzoate orally disintegrating (OD) tablets and placebo. The x-axis represents hours post-dose ranging from 0.5 to 2, and the y-axis shows percent with 95% confidence intervals from 0 to 100%. Rizatriptan Benzoate OD tablets are shown with solid circles and a solid line, while placebo is shown with open circles and a dashed line.*
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)
Chemical structure of Rizatriptan Benzoate, showing the molecular arrangement of its components including the indole ring and benzoate group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.